Long-Term Sustainability and Acceptance of Antimicrobial Stewardship in Intensive Care: A Retrospective Cohort Study.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
01 01 2021
Historique:
pubmed: 17 10 2020
medline: 8 6 2021
entrez: 16 10 2020
Statut: ppublish

Résumé

To evaluate long-term uptake of an antimicrobial stewardship audit-and-feedback program along with potential predictors of stewardship suggestions and acceptance across a diverse ICU population. A retrospective cohort study. An urban, academic medical institution. Patients admitted to an ICU who received an antimicrobial stewardship program suggestion between June 2010 and September 2019. None. The antimicrobial stewardship program provided 7,749 antibiotic assessments over the study period and made a suggestion to alter therapy in 2,826 (36%). Factors associated with a higher likelihood of receiving a suggestion to alter therapy included shorter hospital length of stay prior to antimicrobial stewardship program review (odds ratio 1.15 for ≤ 5 d; 95% CI 1.00-1.32), admission to cardiovascular (1.37; 1.06-1.76) or burn surgery (1.88; 1.50-2.36) versus general medicine, and preceding duration of antibiotic use greater than 5 days (1.33; 1.10-1.60). Assessment of aminoglycosides (2.91; 1.85-4.89), carbapenems (1.93; 1.54-2.41), and vancomycin (2.71; 2.19-3.36) versus ceftriaxone was more likely to result in suggestions to alter therapy. The suggestion acceptance rate was 67% (1,895/2,826), which was stable throughout the study period. Admission to a level 3 ICU was associated with higher likelihood of acceptance of suggestions (1.50; 1.14-1.97). Factors associated with lower acceptance rates were admission to burn surgery (0.64; 0.45-0.91), treatment of pneumonia (0.64; 0.42-0.97 for community-acquired and 0.65; 0.44-0.94 for ventilator-acquired), unknown source of infection (0.66; 0.48-0.92), and suggestion types of "narrow spectrum" (0.65; 0.45-0.94), "change formulation of antibiotic" (0.42; 0.27-0.64), or "change agent of therapy" (0.63; 0.40-0.97) versus "change of dose". An antimicrobial stewardship program implemented over a decade resulted in sustained suggestion and acceptance rates. These findings support the need for a persistent presence of audit-and-feedback over time with more frequent suggestions to alter potentially nephrotoxic agents, increased efforts toward specialized care units, and further work approaching infectious sources that are typically treated without pathogen confirmation and identification.

Identifiants

pubmed: 33060503
pii: 00003246-202101000-00003
doi: 10.1097/CCM.0000000000004698
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19-26

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

Déclaration de conflit d'intérêts

The authors have disclosed that they do not have any potential conflicts of interest.

Références

Pope SD, Dellit TH, Owens RC, et al. Infectious Diseases Society of America; Society for Healthcare Epidemiology of America: Results of survey on implementation of Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Infect Control Hosp Epidemiol. 2009; 30:97–98
Broom J, Broom A, Plage S, et al. Barriers to uptake of antimicrobial advice in a UK hospital: A qualitative study. J Hosp Infect. 2016; 93:418–422
Elligsen M, Walker SA, Pinto R, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: A controlled interrupted time series analysis. Infect Control Hosp Epidemiol. 2012; 33:354–361
Diaz Granados CA. Prospective audit for antimicrobial stewardship in intensive care: Impact on resistance and clinical outcomes. Am J Infect Control. 2012; 40:526–529
Katsios CM, Burry L, Nelson S, et al. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patients. Crit Care. 2012; 16:R216
Malani AN, Richards PG, Kapila S, et al. Clinical and economic outcomes from a community hospital’s antimicrobial stewardship program. Am J Infect Control. 2013; 41:145–148
Lindsay PJ, Rohailla S, Taggart LR, et al. Antimicrobial stewardship and intensive care unit mortality: A systematic review. Clin Infect Dis. 2019; 68:748–756
Peragine C, Walker S, Simor A, et al. Impact of a comprehensive antimicrobial stewardship program on institutional burden of antimicrobial resistance: A 14-year controlled interrupted time-series study. Clin Infect Dis. 2019ciz1183
Elligsen M, Walker SA, Simor A, et al. Prospective audit and feedback of antimicrobial stewardship in critical care: Program implementation, experience, and challenges. Can J Hosp Pharm. 2012; 65:31–36
Palmay L, Elligsen M, Walker SA, et al. Hospital-wide rollout of antimicrobial stewardship: A stepped-wedge randomized trial. Clin Infect Dis. 2014; 59:867–874
Bartlett JM, Siola PL. Implementation and first-year results of an antimicrobial stewardship program at a community hospital. Am J Health Syst Pharm. 2014; 71:943–949
Toth NR, Chambers RM, Davis SL. Implementation of a care bundle for antimicrobial stewardship. Am J Health Syst Pharm. 2010; 67:746–749
Li Z, Cheng B, Zhang K, et al. Pharmacist-driven antimicrobial stewardship in intensive care units in East China: A multicenter prospective cohort study. Am J Infect Control. 2017; 45:983–989
Waters CD. Pharmacist-driven antimicrobial stewardship program in an institution without infectious diseases physician support. Am J Health Syst Pharm. 2015; 72:466–468
Mertz D, Brooks A, Irfan N, et al. Antimicrobial stewardship in the intensive care setting–A review and critical appraisal of the literature. Swiss Med Wkly. 2015; 145:w14220
Sawyer RG, Claridge JA, Nathens AB, et al. STOP-IT Trial Investigators: Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015; 372:1996–2005
Pugh R, Grant C, Cooke RPG, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015; 2015:CD007577
Lachiewicz AM, Hauck CG, Weber DJ, et al. Bacterial infections after burn injuries: Impact of multidrug resistance. Clin Infect Dis. 2017; 65:2130–2136
Lawrence K, Kollef M. Antimicrobial stewardship in the intensive care unit advances and obstacles. AJRCCM. 2009; 176:434–438
Klein Klouwenberg PM, Ong DS, Bos LD, et al. Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med. 2013; 41:2373–2378
Béïque L, Zvonar R. Addressing concerns about changing the route of antimicrobial administration from intravenous to oral in adult inpatients. Can J Hosp Pharm. 2015; 68:318–326
Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: Multicentre randomised trial. BMJ. 2006; 333:1193
Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev. 2007; 2007:CD003237

Auteurs

Prateek Sehgal (P)

Interdepartmental Division of Critical Care Medicine at University of Toronto, Toronto, ON, Canada.
Department of Medicine, University of Toronto, Toronto, ON, Canada.

Marion Elligsen (M)

Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Jennifer Lo (J)

Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Philip W Lam (PW)

Department of Medicine, University of Toronto, Toronto, ON, Canada.
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Jerome A Leis (JA)

Department of Medicine, University of Toronto, Toronto, ON, Canada.
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Rob Fowler (R)

Interdepartmental Division of Critical Care Medicine at University of Toronto, Toronto, ON, Canada.
Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Center, Toronto, ON, Canada.

Ruxandra Pinto (R)

Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Nick Daneman (N)

Department of Medicine, University of Toronto, Toronto, ON, Canada.
Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Center, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH